SNDX · Syndax Pharmaceuticals Inc
Market Cap
$1.74B
Shares
89.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$172.35M
+627.8%
FY2025
Net Income
-$285.42M
+10.5%
FY2025
Operating Margin
-158.45%
+1276pp
FY2025
Diluted EPS
-$3.29
+11.6%
FY2025
Operating Cash Flow
-$322.98M
-17.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $252M | $172.35M | $23.68M | $0 | $0 | $139.71M | $1.52M | $1.52M | $1.52M | $2.11M | $1.22M | $627K | — | |
| $261.8M | $258.78M | $241.65M | $163.03M | $118.5M | $88.25M | $50.44M | $42.99M | $60.11M | $48.2M | $31.67M | $9.55M | $10.18M | |
| — | — | — | — | $33.26M | $25.24M | $22.51M | $16.06M | $17.29M | $15.86M | $13.32M | $11.59M | $11.16M | |
| — | $179.68M | $120.88M | $66.92M | $33.26M | $25.24M | — | — | — | — | — | — | — | |
| $446.18M | $445.44M | $363.35M | $229.95M | $151.76M | $113.49M | $72.94M | $59.06M | $77.39M | $64.06M | $44.99M | $21.14M | $21.33M | |
| -$194.17M | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M | -$71.42M | -$57.54M | -$75.88M | -$61.95M | -$43.77M | -$20.51M | -$21.33M | |
| — | -158.45% | -1434.43% | — | — | 18.77% | -4708.17% | -3792.95% | -5001.71% | -2938.99% | -3587.38% | -3271.61% | — | |
| $2000 | $6000 | -$1000 | $208K | $3.14M | $1.9M | $2.36M | — | — | — | — | — | — | |
| $16.9M | $22.73M | $26.09M | $21.16M | $5.87M | $403K | $841K | $1.57M | $1.94M | — | — | — | — | |
| -$26.59M | -$12.34M | $20.91M | $20.59M | $2.42M | -$1.29M | -$1.74M | $1.49M | $1.92M | $1.15M | -$706K | -$3.61M | $1.5M | |
| $433K | $433K | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$220.77M | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M | -$73.16M | -$56.05M | -$73.96M | -$60.8M | -$44.47M | -$24.12M | -$19.83M | |
| — | -165.6% | -1346.11% | — | — | 17.84% | -4822.54% | -3694.59% | -4875.48% | -2884.35% | -3645.25% | -3846.73% | — | |
| -$220.77M | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M | -$77.06M | -$56.05M | -$73.96M | -$60.8M | -$47.07M | -$103.85M | -$26.36M | |
| — | -$285.13M | -$318.81M | -$208.34M | -$150.19M | -$24.98M | -$73.16M | -$56.02M | -$73.84M | -$61M | -$44.44M | -$24.09M | -$19.83M | |
| USD/shares | -$2.51 | -$3.29 | -$3.72 | -$2.98 | -$2.46 | $0.48 | -$1.87 | -$1.84 | — | — | — | — | — |
| USD/shares | -$2.51 | -$3.29 | -$3.72 | -$2.98 | -$2.46 | $0.46 | -$1.87 | -$1.84 | — | — | — | — | — |
| shares | — | 86.63M | 85.62M | 70.37M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21M | 14.62M | 68.35K | 58.18K |
| shares | — | 86.63M | 85.62M | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21M | 14.62M | 68.35K | 58.18K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.43×
EV/EBIT
—
Peer median 16.92×
P/E (TTM)
—
Peer median 17.50×
Peer medians compare against the 267 similar-size Biotechnology companies (of 524 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Biopharmaceutical Cancer Therapeutics | $172,352,000 | $23,680,000 | $0 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Product Revenues | $124,844,000 | $7,680,000 | $0 | $0 |
| Collaboration Revenue | $42,367,000 | $0 | $0 | — |
| Milestone Revenue | $5,141,000 | $16,000,000 | $0 | $0 |
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
217 filings
214 filers
Visit website
Investor relations